Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$271.97M+9.65%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Caitlin Zulla
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 5,000
- Beta
- 0.99
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 0.97
Financials
LMRI has only 8 quarterly periods on file — the charts below show the full history available.
Revenue
$271.97M+9.7%Net Income
$7.18MEBITDA
$37.79M+30.6%Free Cash Flow
$20.60M+6.0%EPS (diluted)
$0.07Shares Outstanding (diluted)
96.26M+1.8%Operating Expenses
$30.02MCash & Debt
$90.01MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.02B | $-47.10M | $-0.66 |
| 2024 | $948.87M | $-94.10M | $-1.00 |
| 2023 | $935.92M | $-122.23M | $-1.29 |
Valuation
LMRIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (8)
- Newszacks.com·3d ago·Neutral
How Much Upside is Left in Lumexa (LMRI)? Wall Street Analysts Think 30.84% The consensus price target hints at a 30.8% upside potential for Lumexa (LMRI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newszacks.com·5d ago·Neutral
Why Lumexa (LMRI) Might be Well Poised for a Surge Lumexa (LMRI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
Lumexa Imaging Announces Third Quarter 2026 Earnings Conference Call Date RALEIGH, N.C., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation's largest providers of outpatient imaging services, today announced it will release its third quarter 2026 financial and operational results after market close on Tuesday, November 10, 2026. The Company will host a conference call and live webcast to discuss the results at 5:00 p.m. ET.
View source ↗ - Newszacks.com·68d ago·Positive
Lumexa (LMRI) Upgraded to Buy: Here's What You Should Know Lumexa (LMRI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsglobenewswire.com·89d ago·Neutral
…g Announces Participation in Upcoming Investor Conferences RALEIGH, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging Holdings, Inc. (“Lumexa Imaging”) (Nasdaq: LMRI), one of the nation's largest providers of outpatient imaging services, announced today that Caitlin Zulla, CEO, and Tony Martin, CFO, will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference, held in Boston, including a fireside chat at 3:00 PM ET and one-on-one meetings wi…
View source ↗ - Newszacks.com·90d ago·Neutral
Wall Street Analysts See a 36.88% Upside in Lumexa (LMRI): Can the Stock Really Move This High? The consensus price target hints at a 36.9% upside potential for Lumexa (LMRI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newsseekingalpha.com·101d ago·Positive
Lumexa Imaging Holdings, Inc. (LMRI) Q2 2026 Earnings Call Transcript Lumexa Imaging Holdings, Inc. (LMRI) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·102d ago·Neutral
Lumexa Imaging Q2 Earnings Call Highlights Lumexa Imaging NASDAQ: LMRI reported second-quarter revenue growth, higher advanced-imaging volumes and a return to profitability, while narrowing its full-year adjusted EBITDA outlook and reiterating revenue and adjusted earnings-per-share guidance.
View source ↗
Earnings
Thu, Mar 25(in 4 months)
Consensus estimate $0.20 per share
Typical surprise +34.9% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$0.26 vs $0.18beat
- Wed, Aug 12$0.20 vs $0.15beat
- Tue, May 12$0.18 vs $0.12beat
- Thu, Mar 26$-0.38 vs $0.05miss
- Wed, Dec 3$-0.03 vs $0.05miss
Estimates and results for LMRI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LMRI officers and directors.
- Bought
- $477k
- Sold
- —
2 trades
0 trades
- Brodnax Brettbought
- Cooper Henry Leebought
46 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LMRI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
